Halting Neurodegeneration with
Disease Altering Therapeutics

Welcome to AcureX Therapeutics

Our mission is to halt neurodegenerative diseases starting with Parkinson’s Disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinson’s in human trials within two years, followed by candidates for other neurodegenerative diseases.


AcureX’s approach and founding intellectual property are based on discoveries made by the company’s inventor co-founder, Xinnan Wang MD, Ph.D. Using these insights, AcureX has built a mitophagy discovery platform to accelerate drug development and de-risk clinical trials.


The AcureX team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs.

Supported by $4M from the Michael J. Fox Foundation for Parkinson’s Research, the Silverstein Foundation for Parkinson's with GBA and private funding.